MiraVista Diagnostics is an Industry Leading Mycology Reference Laboratory

MiraVista Diagnostics is a CLIA and CAP certified mycology reference laboratory (RL) with an exclusive focus on developing and processing diagnostic tests for serious fungal infections. We offer the highest standards in clinical accuracy and sensitivity for detection, monitoring and diagnostic testing for blastomyces dermatitidis, histoplasma capsulatum, cryptococcus, coccidioides, aspergillus and beta-D glucan.

Clinical Laboratory Testing for Serious Fungal Infections

The company was founded in 2002 by the renowned infectious disease scientist, Dr. Lawrence Joseph Wheat, whose groundbreaking research contributions resulted in the development of the first histoplasmosis antigen test in 1986. Today, MiraVista Diagnostics serves the medical and veterinary sectors in the U.S. and Canada processing over 100,000 tests per year for fungal infections. This includes antigen and antibody detection tests for coccidioides (valley fever fungus), aspergillus, histoplasmosis capsulatum, blastomyes dermatitidis and cryptococcus.

MiraVista Diagnostics offers same-day testing, prompt response, fast shipping and direct access to the laboratory’s team of experienced infectious disease specialists that has collectively published more than 1,000 scientific research articles. Clients include large medical research hospitals, healthcare systems and universities as well as large reference labs and veterinary clinics. Contact us to discuss a fungal infection case, set up a corporate account for high volume testing or order from among MiraVista Diagnostics’ menu of diagnostic screening tests for fungal diseases.

Company News

MiraVista Diagnostics Supports Fungal Disease Awareness Week

August 14–18, 2017, is the first Fungal Disease Awareness Week. CDC and partners have organized this week to highlight the importance of recognizing serious fungal diseases early enough in the course of a patient’s illness to provide life-saving treatment. MiraVista…
READ MORE →

MiraVista is Participating in the 2017 Coccidioidomycosis Study Group Symposium

MiraVista Diagnostics is participating in the 2017 Coccidioidomycosis Study Group Symposium on August 11-13 at the Stanford University Medical School. Representatives from the company’s clinical laboratory will be available to discuss MiraVista’s menu of diagnostic tests for serious fungal infections….
READ MORE →

NEW: MVista® Histoplasma Antibody IgG IgM EIA

Improve Diagnosis of Acute Pulmonary Histoplasmosis by Combining Antigen & Antibody Testing Review the technical specifications for the NEW MVista® Histoplasma Antibody IgG IgM EIA>> CLINICAL BACKGROUND Acute pulmonary histoplasmosis (APH) can be severe, especially following heavy exposure and is…
READ MORE →

BULLETIN: CSTE Revised Its Histoplasmosis Position Statement at the 2016 Annual Conference

The Council of State and Territorial Epidemiologists (CSTE) approved the Infectious Disease Committee’s revisions to the histoplasmosis position statement, “Standardized Surveillance Case Definition for Histoplasmosis” at the organization’s annual conference in Anchorage, Alaska on June 19-23, 2016. Review the revised…
READ MORE →

FEATURE: Diagnosing Histoplasmosis by Antigen Detection

FEATURED CASE REPORT FROM THE DESK OF: Lawrence Joseph Wheat, MD Medical Director, Founder & President of MiraVista Diagnostics Here is an important patient case report I’d like to share with colleagues about diagnosing histoplasmosis by antigen detection. I welcome…
READ MORE →

NEW: MVista® Coccidioides Antibody IgG IgM EIA

Improve Coccidioidomycosis Diagnosis with a New, More Sensitive, Anti-Coccidioides Antibody Enzyme Immunoassay CLINICAL BACKGROUND Coccidioidomycosis is endemic to the southwestern United States, northern Mexico and regions of Central and South America. Coccidioidomycosis often presents as community acquired pneumonia (CAP) and…
READ MORE →

LEARN MORE
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo